Shared on 19 Sep 25
Fair value Increased 1.63%Given the absence of analyst reasoning, the consensus analyst price target for Lonza Group saw only a marginal increase from CHF665.36 to CHF676.18 alongside minimal changes in key valuation metrics such as future P/E and discount rate, indicating steady market expectations and a broadly unchanged fair value outlook. What's in the News Lonza entered a seven-year manufacturing agreement with Avidity Biosciences for commercial drug substance and product, with a minimum purchase commitment of approximately $620 million between 2026 and 2028.
Shared on 23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 0.28%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 5.03%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 1.87%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 12 Mar 25
Fair value Increased 1.25%AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to -0.0%.